Home
Congress & Events
Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically

Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America

Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.

You are Leaving Medically

You are Leaving the Global Medically Site

Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America

Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.

You are Leaving Medically

You are Leaving the Global Medically Site

You need to have cookies enabled to save content